Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T15:35:46.524Z.
Calculation as of: 2026-10-06T15:35:46.524Z.
Quote observation: 2026-10-06T15:35:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2e8745362276acfcd64f5b9abcba69827836693d7b304a16c872192b0535814a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Bicara Therapeutics Inc. Common Stock
Market Cap
$1.11B
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.13B
PS Ratio
1.55
TTM Avg
1.49
3Y Avg
2.58
5Y Avg
3.06
Market Cap
$1.06B
PS Ratio
33.23
TTM Avg
417.15
3Y Avg
424.50
5Y Avg
312.33
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $1.11B | N/A | N/A | N/A | N/A |
| IRadimed Corporation (IRMD)vs › | $1.08B | 12.56 | 14.19 | 10.93 | 10.80 |
| Harrow Health, Inc. (HROW)vs › | $1.13B | 4.11 | 5.90 | 5.82 | 5.19 |
| Amphastar Pharmaceuticals, Inc. (AMPH)vs › | $1.13B | 1.55 | 1.49 | 2.58 | 3.06 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.07B | N/A | 45.53 | 45.53 | 45.53 |
| OPKO Health, Inc. (OPK)vs › | $1.14B | 1.94 | 1.68 | 1.45 | 1.34 |
| GoodRx Holdings, Inc. (GDRX)vs › | $1.15B | 1.47 | 1.25 | 2.39 | 4.44 |
| Teladoc Health, Inc. (TDOC)vs › | $1.06B | 0.42 | 0.48 | 0.66 | 1.86 |
| Janux Therapeutics, Inc. (JANX)vs › | $1.06B | 33.23 | 417.15 | 424.50 | 312.33 |
| Avalyn Pharma Inc. Common Stock (AVLN)vs › | $1.15B | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-30 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-11 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-11 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
